業績 Publication
原著 Original Research Papers
45. Iizuka-Koga M, Ito M, Yumoto N, Mise-Omata S, Hayakawa T, Komai K, Chikuma S, Takahashi S, Matsumoto I, Sumida T, Yoshimura A. Reconstruction of Sjogren's syndrome-like sialadenitis by a defined disease specific gut-reactive single TCR and an autoantibody. Clin Immunol May 16: 110258, 2024
44. Hayabuchi H, Tokifuji Y, Takahashi H, Amagai M, Yoshimura A, Chikuma S (Corresponding Author.) Disruption of post-thymic tolerance in skin-reactive TCR transgenic mice through the interaction of lymphopenia and intestinal microbiota. Int Immunol. Apr 5: dxae018, 2024
43. Tokifuji Y, Hayabuchi H, Sasaki T, Hara-Chikuma M, Hirota K, Takahashi H, Amagai M, Yoshimura A, Chikuma S (Corresponding Author.) Targeting abatacept-resistant T-helper-17 cells by aldehyde dehydrogenase inhibition. iScience 27: 108646, 2023
42. Nakamichi R, Hishikawa A, Chikuma S, Yoshimura A, Sasaki T, Hashiguchi A, Abe T, Tokuhara T, Yoshimoto N, Nishimura ES, Hama EY, Azegami T, Nakayama T, Hayashi K, Itoh H. DNA-damaged podocyte-CD8 T cell crosstalk exacerbates kidney injury by altering DNA methylation. Cell Rep 42: 112427, 2023
41. Miyamoto K, Hayabuchi H, Tokifuji Y, Ando M, Onishi N, Okamura T, Yoshimura A, Chikuma S (Corresponding Author).
A Protein Kinase D inhibitor suppresses AKT on T cells and antagonizes cancer immunotherapy by Anti-PD-1. Int Immunol 16, dxac035, 2022
40. Chikuma S (Corresponding Author)., Yamanaka S, Nakagawa S, Ueda MT, Hayabuchi H, Tokifuji Y, Kanayama M, Okamura T, Arase H, Yoshimura A.
TRIM28 Expression on Dendritic Cells Prevents Excwssive T cell Priming by silessing endogenous retrovirus. J Immunol 2021 Apr 1;206(7):1528-1539
39. Sakai R, Ito M, Yoshimoto K, Chikuma S, Kurasawa T, Kondo T, Suzuki K, Takeuchi T, Amano K, Yoshimura A.
Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis.
Clin Transl Immunology. 9:e1203, 2020
38. Kondo T, Ando M, Nagai N, Tomisato W, Srirat T, Liu B, Mise-Omata S, Ikeda M, Chikuma S, Nishimasu H, Nureki O, Ohmura M, Hayakawa N, Hishiki T, Uchibori R, Ozawa K, Yoshimura A. The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells Cancer Research 80: 471-483, 2020
37,. Kondo T, Imura Y, Ando M, Chikuma S, Yoshimura A
In Vitro Conversion of Activated T Cells into Stem Cell Memory-Like T Cells Methods Mol Biol 2048:41-51.
36 Goto M, .Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T, Miura M,
Yamasaki T, Ogawa S, Sonobe M, Date H, Hamanishi J, Mandai M, Tanaka Y,
Chikuma S, Hatae R Muto M,, Minamiguchi S, Minato M, Honjo T. Analytical
performance of a new automated chemiluminescent magnetic immunoassays for
soluble PD-1, PD-L1, and CTLA-4 in human plasma. Scientific Reports 9:
10144, 2019
35. Tsuda M, Ogawa S, Ooka M, Kobayashi K, Hirota K, Wakasugi M, Matsunaga
T, Sakuma T, Yamamoto T, Chikuma S, Sasanuma H, Debatisse M, Doherty AJ, Fuchs RP, Takeda S PDIP38/PolDIP2
controls the DNA damage tolerance pathways by increasing the relative usage
of translesion DNA synthesis over template switching. PLos One 14: e0213383, 2019.
34. Nakatsukasa H, Oda M, Yin J, Chikuma S, Ito M, Koga-Iizuka M, Someya
K, Kitagawa Y, Ohkura N, Sakaguchi S, Koya I, Sanosaka T, Kohyama J, Tsukada
YI, Yamanaka S, Takamura-Enya T, Lu Q, Yoshimura A Loss of TET proteins
in regulatory T cells promotes abnormal proliferation, FoxP3 destabilization,
and IL-17 expression. Int Immunol. [Epub ahead of print], 2019.
33. Ito M, Komai K, Mise-Omata S. Iizuka-Koga M, Noguchi Y, Kondo T, Sakai
R, Matsuo K, Nakayama T, Yoshie, O, Nakatsukasa H, Chikuma S, Shichita, T, Yoshimura A Brain regulatory T cells suppress astrogliosis
and potentiate neurological recovery. Nature 565: 246-250, 2019.
32. Kanamori M, Nakatsukasa H, Ito M, Chikuma S, Yoshimura A Reprogramming of Th1 cells into regulatory T cellls through
rewiring of the metabolic status. Int Immunol 30: 357-373, 2018.
31. Kondo T, Imura Y, Chikuma S, Hibino S, Omata-Mise S, .Ando M, Akanuma,
T, Iizuka M, Sakai R, Morita R, Yoshimura A Generartion and application
of human induced-stem cell memory T cells for adoptive immunotherapy. Cancer Sci 109: 2130-2149, 2018
30. Hibino S, Chikuma S, Kondo T, Ito M, Nakatsukasa H, Omata-Mise S, Yoshimura A. Inhibition
of Nr4a receptors enhances anti-tumor immunity by breaking Treg-mediated
immune tolerance. Cancer Research Mar 20[Epubahead of print], 2018.
29. Kasahara H, Kondo T, Nakatsukasa H, Chikuma S, Ito M, Amdo M, Kurebayashi Y, Sekiya T, Yamada T, Okamoto S, Yoshimura
A. Genaration of allo-antigen-specific induced Treg stabilized by
vitamine C treatment and its application for acute graft versus host disease
model. Int Immunol 29: 457-469, 2017.
28. Kondo T, Morita R, Okuzono Y, Nakatsukasa H, Sekiya T, Chikuma S, ShichitaT, Kanamori M, Kubo M, Koka K, Miyazaki T, Kassai Y, Yoshimura
A.
Notch-mediated conversion of activated T cells into stem cell
memory-like T cells foradoptive immunotherapy Nature Communications8: 15338, 2017.
27. Komai K, Shichita T, Ito M, Kanamori M, Chikuma S, Yoshimura A Role of scavenger receptors as damage-associated molecular
pattern receptos in TLR activation. Int Immunol.29: 59-70, 2017.
26 Zhang B*, Chikuma S*, Hori S, Fagarasan S, Honjo T Non-overlapping rolesof PD-1 and FoxP3
in maintaining immune tolerance in a novel autoimmune pancreatitis mouse
model. Proc. Nat. Acad .Sci. USA113 8490-5,2016(*:equal contribution)
25 Sakaguchi R, Chikuma S, Shichita T, Morita R, Sekiya T, Ouyang W, Ueda T, SekiH, Morisaki H, Yoshimura
A. Innate-like function of memory Th17 cells for enhancing endotoxin-induced
acute lung inflammation through IL-22.Int Immunol.28, 233-43, 2015
24. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T,
Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K,Ueda A, Hosoe Y, Morita S, Yokode
M, Shimizu A, Honjo T, Konishi I Safety and Antitumor Activity of Anti-PD-1
Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin. Oncol.. 33, 4015-22, 2015
23. Stumpf M, Zhou X, Chikuma S, Bluestone JA Tyrosine 201 of thecytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.Eur. J.Immunol.44: 1737-46, 2014.
22. Nguyen T, Xu J, Chikuma S, Hiai H, Kinoshita K, Moriya K, Koike K, Marcuzzi GP, Pfister H, Honjo
T, Kobayashi M Activation-induced cytidine deaminase is dispensable
for virus-mediated liver and skin tumor development in mouse models. Int. Immunol.26: 397-406, 2014.
21. Rui Y, Honjo T, Chikuma S Programmed cell death 1 inhibits inflammatory helper T-cell development
through controlling the innate immune response. Proc. Nat. Acad .Sci. USA110:16073-8, 2013.
20. Hara-Chikuma M, Chikuma S, Sugiyama Y, Kabashima K, Verkman AS, InoueS, Miyachi Y. Chemokine-dependent
T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake.
J Exp Med 301 245-52, 2012
19.Chikuma S, Suita N, Okazaki IM, Shibayama S, Honjo T. TRIM28 prevents autoinflammatory
T cell development in vivo. Nat. Immunol. 13：596-603, 2012
18. Qin H, Suzuki K, Nakata M, Chikuma S, Izumi N, Huong Le T, Maruya M, Fagarasan, S, Busslinger M, Honjo T, Nagaoka
H. Activation-induced cytidine deaminase expression in CD4+ T cells
is associated with a unique IL-10-producing subset that increases with
age. Plos One ;6: e29141, 2011
17. Terawaki S*, Chikuma S*, Shibayama S*, Hayashi T, Yoshida T, Okazaki T, Honjo T. IFN-α directly
promotes programmed cell death-1 transcription and limits the duration
of T cell-mediated immunity. J. Immunol. 186: 2772-9, 2011 (* equal contribution)
16. Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T PD-1 deficiency
results in the development of fatal myocarditis in MRL mice. Int Immunol 22: 443-52. 2010
15.Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, Okazaki T,
Honjo T. PD-1-mediated suppression of IL-2 production induces CD8+
T cell anergy in vivo. J. Immunol. 1: 182: 6682-9, 2009
14. Jiang F, Yoshida T, Nakaki F, Terawaki S, Chikuma S, Kato Y, Okazaki IM, HonjoT, Okazaki T. Identification of
QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice. Int. Immunol. 21:499-509, 2009.
13. Hara-Chikuma M, Takahashi K, Chikuma S, Verkman AS, Miyachi Y. The expression of differentiation markers
in aquaporin-3 deficient epidermis. Arch Dermatol Res 301: 245-52, 2009
12.Chikuma S, Bluestone JA Expression of CTLA-4 and FOXP3 in cis protects from
lethal lymphoproliferative disease. Eur J Immunol ;37: 1285-9, 2007
11.Chikuma S, Bluestone JA B7 independent T cell inhibition by CTLA-4. J.Immunol 175: 177-81, 2005
10. Ogasawara K, Hamerman J, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL Impairment
of NK cell function by NKG2D modulation in NOD mice. Immunity ;18: :41-51, 2003
9.Chikuma S, Imboden J, Bluestone JA Negative regulation of T cell receptor-lipid
raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 197: 129-35 2003
8. Ijima K, Murakami M, Okamoto H, Inobe M, Chikuma S, Saito I, Kanegae Y, Kawaguchi Y, Kitabatake A, Uede T Successful
gene therapy via intraarticular injection of adenovirus vector containing
CTLA4IgG in a murine model of type II collagen-induced arthritis. Human Gene Therapy 12: 1063-77, 2001
7. Takehara M, Murakami M, Inobe M, Tanaka K, Chikuma S,Saito I, Kanegae Y, Yasunami Y, Nakano M, Yamashita K, Todo S, Uede T
Long-term acceptance of allografts by in vivo gene transfer of regulatable
adenovirus vector containing CTLA4IgG and loxP. Human Gene Therapy 12: 415-26, 2001
6.Chikuma S, Murakami M, Tanaka K, Uede T. Janus kinase 2 is associated with
a box 1-like motif and phosphorylates a critical tyrosine residue in the
cytoplasmic region of cytotoxic T lymphocyte associated molecule-4. J. Cell.Biochem 78: 241-50, 2000
5. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T Antibodies to
different peptides in osteopontin reveal complexities in the various secreted
forms. J Cell Biochem 77: 487-98, 2000
4. Takiguchi M, Murakami M, Nakagawa I, Rashid MM, Tosa N, Chikuma S, Hashimoto A, Uede T. Involvement of CD28/CTLA4-B7 costimulatory
pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr
mice. J Vet Med Sci. 62: 29-36, 2000
3. Takiguchi M, Murakami M, Nakagawa I, Yamada A, Chikuma S, Kawaguchi Y, Hashimoto A, Uede T. Blockade of CD28/CTLA4-B7 pathway
prevented autoantibody-related diseases but not lung disease in MRL/lpr
mice. Laboratory Investigations. 79: 317-26, 1999.
2. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T.
CD44 variants but not CD44s cooperate with beta1-containing integrins
to permit cellsto bind to osteopontin independently of arginine-glycine-aspartic
acid, therebystimulating cell motility and chemotaxis. Cancer Res. 1999 Jan 1;59(1):219-26
1. Nakagawa I, Murakami M, Ijima K, Chikuma S, Saito I, Kanegae Y, Okamoto H, Kitabatake A, Uede T. Persistent
and secondary adenovirus-mediated hepatic gene expression using adenovirus
vector containing CTLA4IgG. Human Gene Therapy. 9: 1739-45, 1998
総説,著書 Review and Books
11.竹馬 俊介 自己免疫寛容におけるFoxP3陽性TregとPD-1 医学のあゆみ 特集「制御性T細胞の現在」 268, 2019.
10. Chikuma S, CTLA-4, an essential immune-checkpoint for T-cell activation. Curr Top Microbiol Immunol410: 99-126, 2017.
9. Yoshimura A, Ito M, Chikuma S, Akanuma T, Nakatsukasa H. Negative regulation of Cytokine Signaling in
Immunity. Cold Spring Harb Perspect Biol. 10: a028571, 2017.
8.Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A SOCS: potential immune checkpoint
molecules for cancer immunotherapy. Cancer Sci. [Epub] Feb, 2017
7.Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016 Feb 10.
6．竹馬 俊介、本庶 佑 「PD-1の機能」 がん分子標的治療 12(1) 51-56, 2014
５. .Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T A rheostat for immune responses: the
unique properties of PD-1 and their advantages for clinical application. Nat. Immunol.14:1212-8, 2013.
4. 竹馬 俊介 「TRIM28による自己炎症性T細胞の制御」、医学のあゆみ 245: 665-6, 2013
3. Chikuma S, Bluestone JA CTLA-4 and tolerance: the biochemical point of view. Immunol. Res.28:241-53, 2003.
2. Chikuma S, Bluestone JA CTLA-4: Acting at the Synapse. Mol Interv 2 :205-8, 2002
1. 竹馬 俊介、上出 利光 可溶性CTLA-4による免疫抑制 臨床免疫 34 665-670、2000
招待講演 Invited Talks at scientific meetings
20 竹馬 俊介 「Ｔ細胞性免疫の、新しい制御機構」 福山大学グリーンサイエンス講演会2018、福山大学、福山市、2018年1月19日
19 竹馬 俊介 「クロマチン制御因子TRIM28によるT細胞免疫の制御」 東海大学マイクロ・ナノ研究開発センター第４０回講演会、東海大学、伊勢原市、2017年9月8日
18 竹馬 俊介 「抑制受容体によるTリンパ球の制御」 岐阜大学医学部分子病態学セミナー、岐阜大学、岐阜市、2016年11月25日
17．竹馬 俊介 「抑制受容体によるリンパ球の制御」、第5回 日大動物医科学センターセミナー、日本大学、藤沢市、2016年10月11日.
16．竹馬 俊介「免疫抑制受容体PD-1の基礎」、第18回癌治療増感研究会シンポジウム、奈良市、2016年2月5日.
15．竹馬 俊介 「PD-1による自己免疫、がん免疫の制御機構」、鹿児島大学呼吸器内科セミナー、鹿児島市、2016年1月15日.
14. 竹馬 俊介 「免疫抑制受容体PD-1の基礎研究と今後の課題」 富山リサーチフォーラム（富山大学医学部内科学第一講座）、、、 富山市、2015年11月13日
13．竹馬 俊介 「抑制受容体PD-1による自己免疫、がん免疫の制御機構」 東海大学医学会講演会、 伊勢原市、2015年7月23日.
12．竹馬 俊介 「PD-1の機能解析とがん治療への応用」 アステラス製薬株式会社 がん免疫セミナー、つくば市、2015年7月31日.
11．竹馬 俊介 「免疫抑制分子によるＴ細胞寛容の制御機構」 第4回産と学をつなぐSENRIの会、豊中市、2014年3月10日.
10. 竹馬 俊介 「がん免疫におけるPD-1」 第17回日本がん分子標的治療学会学術集会シンポジウム 京都市、2013年6月12日〜14日
9．竹馬 俊介 「抑制受容体と核内因子によるT細胞免疫の制御」、東北大学免疫科学コアセンターセミナー、東北大学、仙台、2013年2月8日.
8．竹馬 俊介「核内因子TRIM28による自己炎症性T細胞の制御」 北海道大学 獣医学部 学術交流資金群講演会 「自己免疫疾患研究の最先端」、札幌、2012年11月1日.
7．竹馬 俊介 Regulation of T cell tolerance by epigenetic TRIM28 理化学研究所免疫アレルギー科学総合研究所セミナー、横浜、2012年7月17日.
6．竹馬 俊介 Regulation of T cell tolerance by epigenetic TRIM28 慶応大学 微生物学免疫学セミナー、東京、2012年7月17日.
5．竹馬 俊介「抗PD-1抗体によるがん治療法」 日台癌のトランスレーショナル研究シンポジウム、神戸、2012年11月21日.
4. 竹馬 俊介 「抑制レセプターによるT細胞免疫の制御」 第２５回千葉大学医工学研究会 千葉 2011年11月25日
3. Chikuma S. T cells expression of TRIM28 prevents development of auto-inflammatory
T cells. 2nd Japan-China-Korea Immunology Symposium Dec.4-6, 2011 Osaka
Univ, Japan
2. 竹馬 俊介 Mechanism of PD-1-mediated T cell tolerance 東北大学加齢医学研究所 加齢生体防御セミナー 仙台 2009年9月４日
1. 竹馬 俊介 Regulation of autoimmune diseases by CTLA-4 北海道大学遺伝子病制御研究所特別セミナー 札幌 2004年11月29日